FXE, short for fluorexetamine, is a synthetic dissociative drug in the same chemical family as ketamine and PCP. It emerged on the research chemical market around 2017 and has gained attention as a novel psychoactive substance (NPS) that produces effects frequently compared to ketamine. Its chemical formula is C₁₄H₁₈FNO, and it belongs to a class of compounds called arylcyclohexylamines, which share a common molecular backbone known for producing feelings of detachment from the body and environment.
How FXE Works in the Brain
Like other dissociative drugs, FXE primarily targets NMDA receptors, a type of receptor involved in learning, memory, and sensory processing. Under normal conditions, these receptors allow signals to pass between nerve cells when activated by the neurotransmitter glutamate. FXE blocks this process, reducing communication between brain regions that coordinate your sense of self, your body, and the world around you. The result is the characteristic “dissociated” feeling users describe: a sense of floating, detachment, or being separated from your own thoughts and physical sensations.
FXE also appears to interact with other neurotransmitter systems, though detailed pharmacological studies specific to fluorexetamine remain limited. Structurally related compounds in the arylcyclohexylamine family commonly affect serotonin and dopamine signaling to varying degrees, which may explain some of the mood-altering effects reported alongside the core dissociative experience.
What FXE Feels Like
People who have used FXE most commonly compare the experience to ketamine. Reports collected by the National Drug Early Warning System (NDEWS) describe dissociation as the central effect, with users noting altered perception of time, visual distortions, and a dream-like headspace. At lower amounts, users report mild euphoria and a pleasant sense of detachment. At higher amounts, the experience can become intensely immersive, with some users describing states similar to ketamine’s well-known “k-hole,” a deeply dissociated condition where awareness of the physical body largely disappears.
One effect that stands out in user reports is mania. NDEWS monitoring has flagged repeated mentions of manic-like states during or after FXE use, including racing thoughts, heightened energy, and impulsive behavior. This distinguishes FXE somewhat from ketamine, which tends to be more sedating. The stimulating quality appears to be a consistent feature rather than a rare side effect, making the experience profile somewhat unique among dissociatives.
How FXE Compares to Ketamine and 2-FDCK
FXE sits in a crowded field of ketamine-adjacent substances. The most direct comparison is 2-FDCK (2-fluorodeschloroketamine), another fluorinated analog of ketamine that appeared on the research chemical market before FXE did. Research published in Frontiers in Molecular Neuroscience found that 2-FDCK and ketamine function as reinforcers with nearly identical effectiveness in animal studies. Rats self-administered both substances at similar rates, and their drug-seeking behavior after a period of withdrawal was statistically indistinguishable. This suggests that at least one close structural relative of FXE carries a comparable potential for repeated use and craving as ketamine itself.
FXE differs from both ketamine and 2-FDCK in a few practical ways. Its duration tends to be longer, with effects commonly reported to last 2 to 4 hours compared to ketamine’s roughly 45 to 90 minutes. The manic or stimulating component also sets it apart. Where ketamine is often described as warm, heavy, and sedating, FXE leans more energetic and mentally activating.
Legal Status and Availability
FXE occupies a legal gray area in many countries. It is not specifically scheduled under international drug treaties, but several nations have moved to restrict it under analog acts or blanket bans on novel psychoactive substances. In the United States, it could be prosecuted under the Federal Analogue Act, which treats substances “substantially similar” to Schedule I or II drugs as controlled when intended for human consumption. In the UK, it falls under the Psychoactive Substances Act of 2016, which broadly prohibits the sale of NPS. Several EU member states have individually added it to their controlled substance lists.
Despite these restrictions, FXE remains available through online vendors who market it as a “research chemical.” This labeling is a legal workaround rather than an accurate description: the vast majority of purchases are for personal use, not laboratory research.
Risks and Unknowns
The biggest risk with FXE is how little is known about it. There are no published human clinical trials, no established safety profile, and no reliable data on long-term effects. What is known comes from user self-reports and structural comparisons to better-studied compounds.
Ketamine, the closest well-researched relative, is known to cause bladder damage with heavy, repeated use. It can also impair memory and cognitive function over time. Whether FXE carries identical risks, greater risks, or different risks entirely is unknown. The manic effects reported by users raise additional concerns, since stimulant-like properties in a dissociative could increase the likelihood of risky behavior while a person’s judgment and coordination are impaired.
Because FXE is unregulated, there is also no quality control over what is actually in a given batch. Independent drug-checking services have occasionally found samples sold as FXE that contained other substances entirely, or mixtures of multiple compounds. Without testing, there is no way to verify purity or dose from the packaging alone.